Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

The poor outcome in high molecular risk, hydroxycarbamide resistant/intolerant ET is not ameliorated by ruxolitinib.

O'Sullivan JM, Hamblin A, Yap C, Fox S, Boucher R, Panchal A, Alimam S, Dreau HM, Howard K, Ware P, Cross NC, McMullin MF, Harrison CN, Mead AJ.

Blood. 2019 Oct 2. pii: blood.2019001861. doi: 10.1182/blood.2019001861. [Epub ahead of print]

PMID:
31578205
2.

Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.

Desterro J, McLornan DP, Curto Garcia N, O'Sullivan J, Alimam S, Keohane C, Woodley C, Francis Y, Kordasti S, Radia DH, Harrison CN.

Br J Haematol. 2019 Aug;186(4):561-564. doi: 10.1111/bjh.15968. Epub 2019 May 15.

PMID:
31090926
3.

Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms.

Herlihy N, Harrison CN, McLornan DP.

Haematologica. 2019 Apr;104(4):639-641. doi: 10.3324/haematol.2018.211896. No abstract available.

4.

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N.

Haematologica. 2019 Apr;104(4):659-668. doi: 10.3324/haematol.2018.206151. Epub 2019 Mar 14. Review.

5.

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review.

Ianotto JC, Curto-Garcia N, Lauermanova M, Radia D, Kiladjian JJ, Harrison CN.

Haematologica. 2019 Aug;104(8):1580-1588. doi: 10.3324/haematol.2018.200832. Epub 2019 Jan 24.

6.

A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ; BSH Committee.

Br J Haematol. 2019 Jan;184(2):176-191. doi: 10.1111/bjh.15648. Epub 2018 Nov 27. Review. No abstract available. Erratum in: Br J Haematol. 2019 Apr;185(1):198.

PMID:
30478826
7.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis.

Vannucchi AM, Te Boekhorst PAW, Harrison CN, He G, Caramella M, Niederwieser D, Boyer-Perrard F, Duan M, Francillard N, Molloy B, Wroclawska M, Gisslinger H.

Haematologica. 2019 May;104(5):947-954. doi: 10.3324/haematol.2018.204602. Epub 2018 Nov 15.

8.

A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.

McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, Knapper S, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Harrison CN; British Society for Haematology Guideline.

Br J Haematol. 2019 Jan;184(2):161-175. doi: 10.1111/bjh.15647. Epub 2018 Nov 13. Review. No abstract available.

9.

Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.

Birgegård G, Folkvaljon F, Garmo H, Holmberg L, Besses C, Griesshammer M, Gugliotta L, Wu J, Achenbach H, Kiladjian JJ, Harrison CN.

Leuk Res. 2018 Nov;74:105-109. doi: 10.1016/j.leukres.2018.10.006. Epub 2018 Oct 11.

PMID:
30368038
10.

What is pre-fibrotic myelofibrosis and how should it be managed in 2018?

Curto-Garcia N, Ianotto JC, Harrison CN.

Br J Haematol. 2018 Oct;183(1):23-34. doi: 10.1111/bjh.15562. Epub 2018 Oct 17. Review.

PMID:
30328618
11.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

12.

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

Godfrey AL, Campbell PJ, MacLean C, Buck G, Cook J, Temple J, Wilkins BS, Wheatley K, Nangalia J, Grinfeld J, McMullin MF, Forsyth C, Kiladjian JJ, Green AR, Harrison CN; United Kingdom Medical Research Council Primary Thrombocythemia-1 Study; United Kingdom National Cancer Research Institute Myeloproliferative Neoplasms Subgroup; French Intergroup of Myeloproliferative Neoplasms; and the Australasian Leukaemia and Lymphoma Group.

J Clin Oncol. 2018 Aug 28:JCO2018788414. doi: 10.1200/JCO.2018.78.8414. [Epub ahead of print]

13.

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide.

Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.

Br J Haematol. 2018 Jul;182(2):279-284. doi: 10.1111/bjh.14764. Epub 2017 May 17. No abstract available.

PMID:
29984424
14.

Myelofibrosis: clinicopathologic features, prognosis, and management.

O'Sullivan JM, Harrison CN.

Clin Adv Hematol Oncol. 2018 Feb;16(2):121-131. Review.

PMID:
29741513
15.

Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy.

Harrington PM, Harrison CN.

Expert Rev Hematol. 2018 Apr;11(4):315-324. doi: 10.1080/17474086.2018.1450628. Epub 2018 Mar 20. Review.

PMID:
29516749
16.

SOHO State-of-the-Art Update and Next Questions: MPN.

Bose P, Gotlib J, Harrison CN, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1-12. doi: 10.1016/j.clml.2017.11.008. Review.

17.

Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.

Harrison CN, Vannucchi AM, Platzbecker U, Cervantes F, Gupta V, Lavie D, Passamonti F, Winton EF, Dong H, Kawashima J, Maltzman JD, Kiladjian JJ, Verstovsek S.

Lancet Haematol. 2018 Feb;5(2):e73-e81. doi: 10.1016/S2352-3026(17)30237-5. Epub 2017 Dec 20.

PMID:
29275119
18.

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond.

Harrison CN, McLornan DP.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):489-497. doi: 10.1182/asheducation-2017.1.489. Review.

19.

Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations.

Alimam S, McLornan DP, Jiang J, Radia D, Mufti GJ, Harrison CN.

Haematologica. 2018 Jun;103(6):e234-e236. doi: 10.3324/haematol.2017.180851. Epub 2017 Nov 30. No abstract available.

20.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
21.

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.

Birgegård G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, Wu J, Achenbach H, Kiladjian JJ.

Haematologica. 2018 Jan;103(1):51-60. doi: 10.3324/haematol.2017.174672. Epub 2017 Oct 27.

22.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Harrison CN, Mead AJ, Panchal A, Fox S, Yap C, Gbandi E, Houlton A, Alimam S, Ewing J, Wood M, Chen F, Coppell J, Panoskaltsis N, Knapper S, Ali S, Hamblin A, Scherber R, Dueck AC, Cross NCP, Mesa R, McMullin MF.

Blood. 2017 Oct 26;130(17):1889-1897. doi: 10.1182/blood-2017-05-785790. Epub 2017 Aug 9.

23.

An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms.

Curto-Garcia N, Harrison CN.

Future Oncol. 2018 Jan;14(2):137-150. doi: 10.2217/fon-2017-0298. Epub 2017 Oct 23.

PMID:
29056075
24.

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.

Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F, Harrison CN, Paquette R, Sun W, Naim A, Langmuir P, Dong T, Gopalakrishna P, Gupta V.

J Hematol Oncol. 2017 Sep 29;10(1):156. doi: 10.1186/s13045-017-0527-7.

25.

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN.

Leuk Res. 2017 Oct;61:6-9. doi: 10.1016/j.leukres.2017.08.002. Epub 2017 Aug 10.

PMID:
28843161
26.

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA.

Ann Hematol. 2017 Oct;96(10):1653-1665. doi: 10.1007/s00277-017-3082-y. Epub 2017 Aug 5.

27.

Hb Baden: a rare high affinity haemoglobin variant and its management.

Lee J, Harrison CN.

J Clin Pathol. 2018 Jan;71(1):79-80. doi: 10.1136/jclinpath-2017-204586. Epub 2017 Aug 2.

PMID:
28768701
28.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
29.

Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.

Saeed I, McLornan D, Harrison CN.

Expert Rev Hematol. 2017 Jul;10(7):617-625. doi: 10.1080/17474086.2017.1337507. Epub 2017 Jun 19. Review.

PMID:
28571503
30.

Equivalence of BCSH and WHO diagnostic criteria for ET.

Harrison CN, McMullin MF, Green AR, Mead AJ.

Leukemia. 2017 Jul;31(7):1660. doi: 10.1038/leu.2017.119. Epub 2017 May 5.

PMID:
28474678
31.

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.

Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, Jakucs J, Perkins A, Prasad R, Mayer J, Demeter J, Ganly P, Singer JW, Zhou H, Dean JP, Te Boekhorst PA, Nangalia J, Kiladjian JJ, Harrison CN.

Lancet Haematol. 2017 May;4(5):e225-e236. doi: 10.1016/S2352-3026(17)30027-3. Epub 2017 Mar 20.

PMID:
28336242
32.

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.

Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, Harrison CN.

Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16. No abstract available.

33.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2017 Mar;31(3):775. doi: 10.1038/leu.2016.323. No abstract available.

PMID:
28248313
34.

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy.

Verstovsek S, Harrison CN, Kiladjian JJ, Miller C, Naim AB, Paranagama DC, Habr D, Vannucchi AM.

Leuk Res. 2017 May;56:52-59. doi: 10.1016/j.leukres.2017.01.032. Epub 2017 Jan 31.

35.

JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms.

O'Sullivan JM, Harrison CN.

Mol Cell Endocrinol. 2017 Aug 15;451:71-79. doi: 10.1016/j.mce.2017.01.050. Epub 2017 Feb 3. Review.

PMID:
28167129
36.

Guideline for the investigation and management of eosinophilia.

Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology.

Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. No abstract available.

37.

Emerging treatments for classical myeloproliferative neoplasms.

Vannucchi AM, Harrison CN.

Blood. 2017 Feb 9;129(6):693-703. doi: 10.1182/blood-2016-10-695965. Epub 2016 Dec 27. Review.

PMID:
28028027
38.

Equivalence of BCSH and WHO diagnostic criteria for ET.

Harrison CN, McMullin MF, Green AR, Mead AJ.

Leukemia. 2017 Feb;31(2):527-528. doi: 10.1038/leu.2016.318. Epub 2016 Nov 29. No abstract available. Erratum in: Leukemia. 2017 Jul;31(7):1660.

PMID:
27895337
39.

Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey.

Koren-Michowitz M, Lavi N, Ellis MH, Vannucchi AM, Mesa R, Harrison CN.

Ann Hematol. 2017 Jan;96(1):87-92. doi: 10.1007/s00277-016-2826-4. Epub 2016 Oct 13.

PMID:
27734130
40.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

41.

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.

Harrison CN, Talpaz M, Mead AJ.

Leuk Lymphoma. 2016 Oct;57(10):2259-67. doi: 10.1080/10428194.2016.1195501. Epub 2016 Jul 27. Review.

42.

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis.

Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN.

Br J Haematol. 2016 Oct;175(1):37-42. doi: 10.1111/bjh.14173. Epub 2016 Jun 13.

PMID:
27293069
43.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T.

Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23. Erratum in: Leukemia. 2017 Mar;31(3):775.

44.

Safety considerations when treating myelofibrosis.

O'Sullivan JM, McLornan DP, Harrison CN.

Expert Opin Drug Saf. 2016 Sep;15(9):1185-92. doi: 10.1080/14740338.2016.1185414. Epub 2016 Jun 1. Review.

PMID:
27187785
45.

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms.

Curto-García N, Harrison CN, McLornan DP, Radia DH.

Br J Haematol. 2017 Jul;178(2):338-340. doi: 10.1111/bjh.14128. Epub 2016 May 2. No abstract available.

PMID:
27135305
46.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.

Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ.

Haematologica. 2016 Jul;101(7):821-9. doi: 10.3324/haematol.2016.143644. Epub 2016 Apr 21.

47.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA.

Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

48.

JAK inhibitors truly changing the therapeutic paradigm in myelofibrosis.

Harrison CN.

J Med Econ. 2016;19(4):443-4. doi: 10.3111/13696998.2016.1149073. Epub 2016 Feb 18. No abstract available.

PMID:
26887425
49.

Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis.

Dowse R, Ibrahim M, McLornan DP, Moonim MT, Harrison CN, Radia DH.

Br J Haematol. 2017 Jan;176(2):324-327. doi: 10.1111/bjh.13951. Epub 2016 Feb 5. No abstract available.

PMID:
26847591
50.

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?

Beauverd Y, McLornan DP, Radia DH, Harrison CN.

Future Oncol. 2016 Mar;12(6):739-49. doi: 10.2217/fon-2015-0023. Epub 2016 Feb 5. Review.

PMID:
26846873

Supplemental Content

Loading ...
Support Center